SLC25A34 Links Body-Clock Signals With Fat-Cell Energy Use

On October 1, 2026, Medical Xpress reported on SLC25A34 research published in Science by the University of Copenhagen’s Novo Nordisk Foundation Center for Basic Metabolic Research. The study was titled “Mitochondrial carrier SLC25A34 links clock, diet, and temperature control of adipocyte lipid cycling.”

The central finding

The team reported that SLC25A34 helps connect the body clock, temperature and dietary signals with how fat cells store and use energy. Across 24 clinical studies, higher SLC25A34 expression in human subcutaneous white fat was also associated with leanness and better metabolic health. For longevity research, the contribution is a candidate explanation of metabolic regulation rather than a measured improvement in healthspan or lifespan.

Study setting: Animal models in mice, in vitro experiments using human donor cells, and observational studies in humans.

How signals converge

The study brings several inputs into the same biological picture rather than treating daily timing and fuel availability as separate processes. As Genetic Engineering & Biotechnology News describes the findings, SLC25A34 sits at an intersection between these signals and fat-cell energy handling. That makes the work relevant to understanding fat tissue’s role in whole-body metabolism.

A daily rhythm

Medical Xpress describes brown fat as tissue that burns fuel to generate heat. Its activity follows a daily rhythm: it falls during sleep and rises before waking. The researchers connected SLC25A34 regulation to that timing pattern.

In the reported regulatory model, the clock protein REV-ERBα suppresses the SLC25A34 gene during sleep. That suppression is released before waking. The result places control of the protein within a schedule that matches changing demands on brown fat.

This is the timing component of the study’s central idea. Rather than asking only how much fuel a cell burns, the work also asks how the machinery involved is regulated across the day. Timing becomes part of the metabolic question rather than background context.

Cold changes timing

The researchers also reported that cold could override the daily schedule. In mice, brown-fat SLC25A34 levels rose 90-fold after 24 hours in the cold. That result helped identify the protein as responsive to temperature as well as circadian regulation.

The measurement needs to stay attached to what was measured: SLC25A34 levels in mouse brown fat. It was not a measurement of a matching increase in fuel burning. Its mechanistic importance lies in showing that the protein’s abundance can respond strongly to a temperature signal within that experimental setting.

Storage meets burning

Diet-related regulation added another layer. The team described fat-related signals acting through PPARα. Both fasting and insulin increased SLC25A34 levels in the reported experiments despite their differing roles in fat use and storage.

That paired response complicates the idea of a simple fat-burning switch. First author Iuliia Karavaeva described the transporter as appearing necessary for both building fat and burning it. In that account, SLC25A34 participates in managing fat rather than pushing metabolism in only one direction.

This distinction matters when interpreting the phrase “lipid cycling” in the paper’s title. The biological story includes both storage and use. Reducing it to “more protein means more fat burning” would leave out a central feature of the researchers’ explanation.

Testing the link

The team then examined what happened when SLC25A34 was depleted. Brown fat burned less fuel in mice. Silencing the protein in cultured brown-fat cells from four human donors reduced fuel burning in cells from three donors.

These experiments add a functional test to the regulatory observations. Instead of only comparing samples with different SLC25A34 levels, the researchers reduced it and examined the metabolic response. The shared direction of the mouse and donor-cell findings supports a role for the protein in fuel use across those experimental settings.

The donor-cell work also provides a specific connection to human cellular biology. Its contribution is different from the association found in human subcutaneous white fat: one approach changes SLC25A34 in an experiment while the other compares its expression with metabolic characteristics. Keeping those approaches separate makes the evidence easier to interpret.

A proposed cargo

The researchers propose that SLC25A34 transports oxaloacetate into mitochondria. This supplies a candidate molecular explanation for how the protein could connect regulatory signals with changes in fat-cell metabolism. It moves the question from whether the protein matters toward how it might work.

That distinction is useful when reading mechanistic research. Evidence that reducing a protein changes cell behavior addresses its functional role. Identifying the substance it transports addresses a more specific molecular question. Both belong in the explanation rather than being treated as interchangeable findings.

Corresponding author Zach Gerhart-Hines said the work raises the possibility of therapies that shift when and how the body burns fuel. As reported by Medical Xpress and Genetic Engineering & Biotechnology News, he described this as a potentially different lever from current obesity and diabetes treatments. That is the research rationale for pursuing the pathway further.

Where evidence stops

The findings form a coherent metabolic story. Several boundaries still determine how much weight to give it:

• The human association does not establish cause. Higher SLC25A34 expression was associated with leanness and better metabolic health. The researchers explicitly caution that this does not show that increasing SLC25A34 would produce those characteristics. An association and a successful intervention answer different questions.
• The donor-cell experiment was small. Cells from four donors provide a preliminary view of human cellular responses. The available coverage does not report the size of the reduction in fuel burning. Cultured cells also cannot establish what would happen in a living person.
• The clinical summary lacks key detail. The coverage reports an association across 24 clinical studies but does not provide pooled participant numbers or effect sizes. The study count therefore should not stand in for a complete assessment of how large or consistent the association was.
• Depletion is not enhancement. Showing that fuel burning falls when SLC25A34 is reduced does not establish that raising it would improve metabolism. A proposed intervention would need evidence about the consequences of increasing its activity rather than relying on the loss-of-function result alone.
• The proposed transport remains unconfirmed. The researchers had not directly demonstrated oxaloacetate transport by SLC25A34. That step remains a hypothesis within the mechanistic account. It should not be presented as an established property simply because the broader metabolic findings fit the proposal.
• Its wider functions need clarification. Karavaeva noted that SLC25A34 is highly expressed in the heart and implicated in brain and liver metabolism. Its functions in those tissues remain unclear. Those observations connect the work with broader questions about the liver’s role in energy handling without resolving them.
• Clinical translation has not been demonstrated. The coverage reports no SLC25A34-targeted treatment or human clinical trial. It also reports no demonstrated clinical benefit from manipulating the protein. Gerhart-Hines’s therapeutic suggestion is therefore a direction for investigation rather than an available option for patients.

The practical takeaway is to treat this as a study of metabolic regulation rather than a nutrition protocol. The cited work does not test changing meal timing, seeking cold exposure or using a supplement to manipulate SLC25A34. Personal decisions about metabolic health belong in discussions with qualified clinicians rather than attempts to reproduce a laboratory signal.

For readers assessing future coverage, the useful question is what each experiment actually measured. Protein levels and cellular fuel use are different endpoints from patient health outcomes. That same reading habit helps when judging claims built around biological-age measurements: identify the measurement before assigning it a broader meaning.

The next test

Direct transport assays followed by carefully designed human intervention studies are the logical next steps toward determining whether this metabolic pathway has any relevance to healthy aging.

How AgeAmaze helps

A fat-cell protein should not become a human health claim simply because an experiment includes donor cells; AgeAmaze keeps the evidence setting visible when explaining longevity science. Its research-led explanations help skeptical adults separate mouse results from human evidence and assess emerging metabolic findings without mistaking laboratory activity for a treatment outcome.

Read the research

Sources

1. A molecular switch syncs fat burning to the body clock, our diet and the temperature around us
2. Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning